Global Monoclonal Antibodies Market 2018-2022
|発行||TechNavio (Infiniti Research Ltd.)||商品コード||364925|
|出版日||ページ情報||英文 115 Pages
|モノクローナル抗体の世界市場：2018年～2022年 Global Monoclonal Antibodies Market 2018-2022|
|出版日: 2018年12月07日||ページ情報: 英文 115 Pages||
Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies. Technavio's analysts have predicted that the monoclonal antibodies market will register a CAGR of about 15% by 2022.
The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.
Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.
For the detailed list of factors that will drive and challenge the growth of the monoclonal antibodies market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Johnson & Johnson and Merck the competitive environment is quite intense. Factors such as the rise in the number of companies venturing into monoclonal antibodies space and the introduction of low cost biosimilar monoclonal antibodies, will provide considerable growth opportunities to monoclonal antibodies manufactures. AbbVie, Amgen, Johnson & Johnson, and Merck are some of the major companies covered in this report.